A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

Trial Details

NCT ID
NCT05860374
Phase
EARLY_PHASE1
Sponsor
Shanghai Yunying Medical Technology
Status
RECRUITING
Cancer Type
Gastric Cancer
Locations (sample)
  • Shanghai, Jiangsu, China

Key Eligibility Criteria

  • Patients with solid tumors clearly diagnosed by histology and/or cytology.
  • Failure of standard treatment or patient unwillingness to receive other antitumor therapy.
  • Age 18 to 75 years.
  • Subjects with ECoG score of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →